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ABSTRACT
The discovery of the HD (Huntington’s disease) gene in
1993 led to the creation of genetic mouse models of the
disease and opened the doors for mechanistic studies. In
particular, the early changes and progression of the disease
could be followed and examined systematically. The present
review focuses on the contribution of these genetic mouse
models to the understanding of functional changes in
neurons as the HD phenotype progresses, and concentrates
on two brain areas: the striatum, the site of most
conspicuous pathology in HD, and the cortex, a site that
is becoming increasingly important in understanding the
widespread behavioural abnormalities. Mounting evidence
points to synaptic abnormalities in communication
between the cortex and striatum and cell–cell interactions
as major determinants of HD symptoms, even in the
absence of severe neuronal degeneration and death.
Key words: excitatory amino acid, Huntington’s disease,
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WHAT IS HUNTINGTON’S DISEASE?
HD (Huntington’s disease) is a progressive, debilitating, and
fatal neurological disorder. Its principal symptoms include
chorea (uncontrollable dance-like movements), cognitive
disturbances, depression and other psychiatric changes
(Harper, 1996). HD is inherited in an autosomal dominant
fashion. The mutated gene is located on the short arm of
chromosome 4 and contains an expansion in the normal
number of CAG (glutamine) repeats, generally .40 (The
Huntington’s Disease Collaborative Research Group, 1993). It
is believed that the severity of symptoms is directly correlated
with the number of CAG repeats (Harper and Jones, 2002). HD
is typically a late-onset disease, although juvenile variants
occur, generally when more CAG repeats are present. In
young children with HD, the symptoms also include epileptic
seizures (van Dijk et al., 1986; Rasmussen et al., 2000;
Gambardella et al., 2001; Seneca et al., 2004). The protein
encoded by the HD gene, htt (huntingtin), is normally a
cytoplasmic protein closely associated with vesicle mem-
branes and microtubules. Although its normal function is not
completely understood, considerable evidence suggests it has
a role in vesicle trafficking, exocytosis and endocytosis
(DiFiglia et al., 1995; Caviston and Holzbaur, 2009).
Neuropathologically, HD is primarily characterized by loss
of MSSNs (medium-sized spiny projection neurons) in the
striatum (caudate nucleus and putamen) and pyramidal
neurons in the cerebral cortex (Vonsattel et al., 1985). Striatal
and cortical interneurons are relatively spared (Vonsattel and
DiFiglia, 1998). Cell loss leads to substantial atrophy of the
striatum, enlarged lateral ventricles, and thinning of the
cortical mantle (Rosas et al., 2005). Within the striatum,
MSSNs that project to the external globus pallidus (indirect
pathway) are the most vulnerable (Reiner et al., 1988; Albin et
al., 1992). These neurons express enk (enkephalin) and DA
(dopamine) D2 receptors. In contrast, MSSNs that project to
the substantia nigra pars reticulata (direct pathway), express
SP (substance P) and DA D1 receptors (Gerfen et al., 1990),
and become affected later in the course of the disorder.
Another pathological landmark of HD is the presence of
aggregated forms of mutant htt in neurons. These aggregates
comprise intranuclear [NII (neuronal intranuclear inclusion)]
and cytoplasmic inclusions, as well as microaggregates. The
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asnneuro.org / Volume 2 (2) / art:e00033 103role of inclusions in cell death is controversial as there is
evidence for both deleterious and protective effects (Ho et al.,
2001; Arrasate et al., 2004; Reiner et al., 2007). Alterations in
the hypothalamus and the endocrine system (e.g. loss of
orexin-containing cells and increased cortisol levels), also play
an important role in the manifestation of HD symptoms
(Petersen et al., 2005; Bjorkqvist et al., 2006; Aziz et al., 2009;
Petersen et al., 2009). Dysfunction in these systems lead to
sleep and metabolic disturbances. Finally, widespread patho-
logy in peripheral tissues including skeletal muscle, heart,
bone and testis, are beginning to be recognized. These
changes are independent of brain dysfunction and appear to
be related to the expression of mutant htt in peripheral
tissues (van der Burg et al., 2009).
EARLY ANIMAL MODELS OF HD
In the late 1970s, several lines of investigation converged to
generate animal models of HD (Coyle, 1979). First, glutamate
was shown to be the main excitatory amino acid in the brain
[reviewed in (Watkins and Jane, 2006)]. Secondly, glutamate
also was shown to be the transmitter of the corticostriatal
projection providing the major excitatory input to the
striatum (McGeer et al., 1977; Fonnum et al., 1981). Finally,
specific glutamate analogues were shown to produce
selective, axon-sparing lesions in the brain (Coyle et al.,
1978). As striatal cell loss is the primary neuropathological
landmark in HD, one of the first rodent models used the
excitotoxin kainic acid to selectively destroy striatal MSSNs
(Coyle and Schwarcz, 1976; Schwarcz and Coyle, 1977). Later,
quinolinic acid [a selective NMDA (N-methyl-D-aspartate)
receptor agonist] was used as it better replicated the
neuropathology seen in HD (Schwarcz et al., 1983). Thus
the roles of glutamate transmission and postsynaptic NMDA
receptors became important and generated the core of the
excitotoxicity hypothesis of HD which posits that striatal
neurons degenerate in HD because of enhanced glutamate
neurotransmission.
As deficits in energy metabolism also occur in HD, other
models that targeted mitochondrial function were developed.
Inhibition of complex II with 3-nitropropionic acid became a
useful model of HD because it produced lesions in the
striatum that were similar to the cell loss in HD (Beal et al.,
1993; Damiano et al., 2009). The major advantage of both the
excitotoxic and the 3-nitropropionic acid models was that the
neuropathology was replicated in non-human primates
(Brouillet et al., 1995).
Although toxic models were instrumental in the under-
standing of some of the mechanisms involved in cell death
(DiFiglia, 1990), they were limited because it was not possible
to study the progression of the disease or to replicate the
widespread neuropathology observed in the human con-
dition. This fact is important as, although it was generally
believed that the progression of symptoms in HD was due to
neurodegeneration of MSSNs, studies in genetic animal
models have demonstrated that severe neuronal dysfunction
precedes degeneration and is probably the major cause of
many symptoms (Levine et al., 2004). The discovery of the HD
gene in 1993 led to the creation of genetic models of the
disease and opened the doors for mechanistic studies.
GENETIC MOUSE MODELS
Genetic mouse models of HD permit examination of the
progression of the disease in detail. The first mouse model of
HD was created in the laboratory of Gillian Bates (Mangiarini
et al., 1996). Since then, numerous genetic mouse models
have been generated. These models include transgenic (with
truncated or full-length human mutant genes), knock-in and
conditional models. We would like to point out that the
models we describe in this review do not represent an
exhaustive or complete list. Only those models deemed
relevant for our major points are included. We apologize in
advance for not citing other important models that also have
added to our understanding of HD mechanisms.
FRAGMENT MODELS
The R6 line of transgenic mice (Mangiarini et al., 1996)
remains one of the most widely used models, not only
because it was the first genetic mouse model generated, but
because it offers many advantages. In particular, R6/2 mice
(with approx. 150 CAG repeats) manifest a very aggressive,
rapidly progressing form of HD, similar to the juvenile form in
humans. R6/2 mice display overt behavioural symptoms as
early as 4–5 weeks of age, show hindlimb clasping and weight
loss and die at approx. 15 weeks. Alterations include the
formation of NIIs (Davies et al., 1997), which were later also
shown to be present in human HD brains (DiFiglia et al.,
1997). NIIs can be observed very early, in the presymptomatic
stage (Morton et al., 2000). There are also changes in
neurotransmitter receptor expression (Cha et al., 1998; Ariano
et al., 2002) and altered signalling mechanisms (Bibb et al.,
2000; Luthi-Carter et al., 2000; Menalled et al., 2000). Many
of these alterations are correlated with motor (Carter et al.,
1999) and learning impairments on a number of cognitive
tasks (Lione et al., 1999), as well as deficits in synaptic
plasticity at hippocampal CA1 (cornu ammonis 1) synapses
before an overt phenotype appears (Murphy et al., 2000).
Another line, the R6/1 (with approx. 110 CAG repeats and
decreased mutant htt expression compared with the R6/2),
presents with similar phenotypic alterations as the R6/2, but
in a more protracted form (Mangiarini et al., 1996). Weight
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become more pronounced with age. In addition, aberrant
synaptic plasticity, which occurs prior to the formation of
nuclear aggregates, has been described in these mice
(Cummings et al., 2006; Milnerwood et al., 2006).
FULL-LENGTH MODELS
The most widely studied full-length model uses YAC (yeast
artificial chromosomes) expressing normal (YAC18) and
mutant (YAC46 and YAC72, and YAC128) htt (Hodgson et
al., 1999; Slow et al., 2003). YAC72 mice display abnormal
behaviour around 7 months of age, as well as selective
degeneration of MSSNs in the lateral striatum by 12 months.
Subsequent experiments in these mice showed that the
formation of aggregates may not be essential to initiate
neuronal death (Hodgson et al., 1999). An increase in CAG
repeat length led to a more severe phenotype, arguing in
favour of a gene–dose effect. YAC128 mice display alterations
similar to YAC72 mice, but these alterations are more severe
and occur earlier (Slow et al., 2003). YAC128 mice exhibit
increased open-field activity at approx. 3 months, followed
by rotarod abnormalities at 6 months. By 12 months, open-
field activity is diminished significantly compared with
controls. In addition, atrophy and neuronal loss (approx.
10%) occur in the striatum and cortex of YAC128 mice (Van
Raamsdonk et al., 2005).
A recently described full-length model of HD uses a BAC
(bacterial artificial chromosome)-expressing mutant htt with
97 glutamine repeats (Gray et al., 2008b). These mice exhibit
progressive motor deficits, neuronal synaptic dysfunction and
late-onset selective neuropathology in both the striatum and
cortex. Interestingly, studies in BACHD mice revealed that the
pathogenic process can occur without early and diffuse
nuclear accumulation of aggregated mutant htt (Gray et al.,
2008b). BAC models also have been instrumental in
demonstrating an important role of cell–cell interactions,
compared with cell autonomous processes, in HD pathogen-
esis (Gu et al., 2005, 2007; Gray et al., 2008a). However, cell
autonomous processes also occur. In a different HD model
(N171-98Q), striatal expression of mutant htt was sufficient
to produce NIIs and motor impairment, which the investiga-
tors attributed to cell-autonomous transcriptional dysregula-
tion (Brown et al., 2008).
KNOCK-IN MODELS
Knock-in models also contributed to our understanding of
HD. The major advantage of these models is that they express
full-length htt in its native genomic context. Several models
that differ mainly in the number of CAG repeats (from 48 to
200) have been generated (White et al., 1997; Levine et al.,
1999; Shelbourne et al., 1999; Wheeler et al., 2000; Lin et al.,
2001; Heng et al., 2007). Although overt behavioural changes
are often subtle in knock-in mice, sensitive and careful
testing demonstrates abnormalities as early as 1–2 months of
age (Menalled et al., 2002, 2003). Furthermore, a consistent
feature of knock-in mice is the presence of nuclear staining
and microaggregates at 2–6 months, which is relatively early
in the course of the disease. By contrast, NIIs are observed
only in older mice (10–18 months) (Menalled et al., 2002),
and loss of MSSNs occurs at approx. 2 years (Hickey et al.,
2008). Two additional knock-in models, the HdhQ150 and
HdhQ200, display a behavioural phenotype that is CAG-
length dependent, with motor abnormalities appearing at 50
or 100 weeks of age and reduced DA receptors in
heterozygotes (Heng et al., 2007, 2009). The HdhQ200 mice
also show regional-selective pathology in the striatum and
cortex, including NIIs and gliosis, and display age-dependent
weight loss beginning at approx. 70 weeks (Heng et al., 2009).
CONDITIONAL MODELS
An important step in the understanding of HD pathology was
the creation of conditional mouse models of the disease.
Taking advantage of the tetracycline-regulatable system,
mutated htt can be ‘turned off’ after being expressed in the
brain (Yamamoto et al., 2000). One contribution of this model
was the demonstration of a close relationship between the
HD phenotype and the presence of NIIs. Interrupting the
expression of mutant htt led to inclusion clearance and a
reversal of motor symptoms. Thus a continuous influx of
mutant htt seems to be required to support inclusions and
symptoms. Autophagy, via acetylation, appears to play a
critical role in this effect (Jeong et al., 2009).
USING MOUSE MODELS TO UNDERSTAND
MECHANISMS
As pointed out above, HD mouse models provide a way to
follow the progression of the disorder especially before overt
symptoms are present. Since each model is unique, similar
phenotypic changes in different models provide a way to
validate alterations and to make sure such changes are not
due to idiosyncratic effects of variables relating to a
particular mouse model. However, no mouse model recapi-
tulates the human condition in its entirety, nor displays the
degree of neurodegeneration that occurs in humans (Levine
et al., 2004). Regardless, each model provides relevant
information for the understanding of HD mechanisms.
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105It has been argued that knock-in models are more faithful
in terms of genetic context and in recapitulating the late
onset, slow natural progression and neuropathology of HD
(Heng et al., 2008). However, in these models the symptoms
are generally mild and normal aging may be a confounding
factor. The R6/2 model has been criticized for the rapid onset
and aggressive development of the phenotype, as well as
early and widespread presence of NIIs. This has raised
questions about its validity for drug screening (Heng et al.,
2008), even though it has been standardly used in many
screening experiments (Gil and Rego, 2009), and whether or
not it recapitulates adult-onset HD since many of the
phenotypic properties of the model are similar to juvenile HD
(Cummings et al., 2009). The conclusion from a careful and
systematic comparison of fragment and full-length knock-in
models of HD was that, when strain background and CAG
repeat length are controlled for, fragment and knock-in
models develop comparable phenotypes (Woodman et al.,
2007). Full-length models, such as the BACHD and the YAC,
display a more robust phenotype than knock-in models, but
they also have shortcomings. In particular, these mice tend to
be heavier than their WT (wild-type) littermates. In human
HD and in other genetic mouse models, weight loss is the
common denominator. The increased body weight in these
models has been associated with overexpression of htt (Van
Raamsdonk et al., 2006). Interestingly, in contrast with R6/2
and some of the knock-in mice where there are considerable
alterations in receptor expression, alterations in YAC128 mice
appear limited to glutamate receptors, as DA, GABA (c-
aminobutyric acid) and adenosine receptor binding remained
unchanged (Benn et al., 2007).
NEURONAL MORPHOLOGICAL AND
FUNCTIONAL ALTERATIONS
As in the human disease, most mouse models of HD display
significant reductions in brain volume. However, in mice
this is probably not the result of a decrease in the number
of neurons. Instead, reduced somatic size and loss or
thinning of dendrites and spines are the main contributors
(Klapstein et al., 2001). The lack of cell loss should not be
surprising and could be related to the resiliency of neurons
in mouse compared with the human brain. For example,
most genetic mouse models of Parkinson’s disease have
been unable to reproduce significant loss of DA cells even
though functional changes occur (Goldberg et al., 2003;
Itier et al., 2003; Kitada et al., 2009; Watson et al., 2009;
Wu et al., 2009). Similarly, it is probable that the majority
of symptoms in mice can be attributed to functional rather
than structural alterations. In particular, changes in
voltage- and ligand-gated ion-channel function and
alterations in synaptic activity occur and become more
pronounced with disease progression (Cepeda et al., 2007).
At this point it remains unknown whether morphological
changes are produced by initial functional alterations or if
these alterations are the consequence of gene-induced
structural abnormalities.
NMDA RECEPTOR-MEDIATED RESPONSES IN
HD MOUSE MODELS
As pointed out above, the excitotoxicity hypothesis, based on
the acute toxicity models, was the initial underlying
hypothesis used to explain neurodegeneration in HD.
Accordingly, increased glutamate release and sensitivity of
NMDA receptors caused striatal cell death. Thus initial studies
in mouse models were aimed at verifying or refuting this
hypothesis. The two most vulnerable areas in HD are the
striatum, especially the MSSNs, and the cerebral cortex. The
R6/2 line has been particularly useful to verify the
excitotoxicity hypothesis. The rapid progression of the disease
allows electrophysiological studies in brain slices which
require visualization of individual neurons with infrared
videomicroscopy and IR-DIC (infrared differential interfer-
ence contrast) optics, a technique better suited for younger
animals. Our laboratory performed one of the first studies
examining NMDA receptor function in genetic mouse models
of HD. Long-lasting bath application of NMDA induces cell
swelling, an index of excitotoxicity that can be visualized
using IR-DIC microscopy (Dodt et al., 1993; Colwell and
Levine, 1996). In striatal slices from symptomatic R6/2 mice
and CAG94 (but not CAG72) knock-in mice, NMDA-induced
cell swelling was enhanced compared with slices from control
mice (Levine et al., 1999), thus providing evidence for the
excitotoxicity hypothesis. In contrast, in vivo studies from
another laboratory using R6/1 mice showed that injections of
quinolinic acid produced less damage in HD mice (Hansson et
al., 1999). Initially, these differences were difficult to explain.
However, it is well-known that, in vivo, excitotoxic lesions
require the integrity of the glutamatergic corticostriatal
pathway (McGeer et al., 1978). Subsequently we showed that
the corticostriatal connection is compromised in the R6 mice
as well as in other mouse models which then reduces the
excitotoxic response in these models. Interestingly, in other
models [e.g. the CAG100 (Laforet et al., 2001)], in vivo
neuroprotection to quinolinic acid did not occur (Petersen et
al., 2002) and in the YAC72 model neurotoxicity was
enhanced (Zeron et al., 2002). Increased NMDA receptor
function was also verified using electrophysiological record-
ings and calcium imaging showing that a population of
MSSNs had increased responses to NMDA (Cepeda et al.,
2001). Similar findings have been obtained in YAC72
(Hodgson et al., 1999) and 128 (Graham et al., 2009) mice.
Another significant alteration in striatal NMDA receptor
function is the early and persistent reduction of Mg
2+
sensitivity (Table 1). When the cell membrane is hyperpolar-
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mV), NMDA receptor channels are blocked by Mg
2+ (Nowak
et al., 1984). The channel activates upon membrane
depolarization or in conditions of reduced Mg
2+ block. In
HD, it appears that NMDA receptors of MSSNs are
potentially activated at more hyperpolarized potentials,
which could be deleterious for the cell. Increased NMDA
currents due to reduced Mg
2+ sensitivity are observed in
MSSNs of symptomatic R6/2 mice (Cepeda et al., 2001)
and in a subset of neurons in young mice (Starling et al.,
2005). In addition, this alteration appears to be intrinsic to
MSSNs, i.e. cell autonomous, as it occurs even after
inactivation of mutant htt in the cortex (Gu et al., 2007).
Surprisingly, cortical pyramidal neurons of R6/2 mice at
similar ages display increased Mg
2+ sensitivity, thus leading
to reduced NMDA currents (Andre ´ et al., 2006). This
alteration could underlie the cognitive impairments found
in HD mice.
RESTING MEMBRANE POTENTIALS AND IONIC
CONDUCTANCE ALTERATIONS
In the striatum, other signs of functional pathology seen in
MSSNs of HD mice are increases in cell membrane input
resistance and depolarized resting membrane potentials
(Levine et al., 1999; Klapstein et al., 2001; see Table 1).
Determinants of these biophysical parameters are cell size
and K
+ conductances, in particular those dependent on leak
and inwardly rectifying K
+ channels. Cell size is decreased in
HD mice (Levine et al., 1999; Klapstein et al., 2001) and K
+
conductances are reduced (Ariano et al., 2005). We examined
changes in inward rectification in R6/2 mice and found a
significant reduction concomitant to the onset of overt
behavioural symptoms. In addition, correlative immunofluor-
escence studies demonstrated decreases in the expression of
K
+ channel subunit proteins, Kir2.1 and Kir2.3 (Ariano et al.,
Table 1 Intrinsic and synaptic alterations in cortical and striatal neurons in mouse models of HD
Electrophysiological alterations in cortical and striatal neurons from R6/1, R6/2 and YAC mouse models of HD during early (E) and
late (L) stages of the disease. In early HD, pre-symptomatic and early symptomatic (mean age of 6 weeks in R6 models and 9 weeks in
most other models), changes in MSSN cell properties include increased membrane input resistance, reduced cell capacitance and a
decrease in K
+ channel inward rectification. These alterations in cell properties, including the appearance of depolarized resting
membrane potentials, are seen also in MSSNs from behaviourally symptomatic mice. In cortical pyramidal neurons from HD mice,
similar changes in cell properties are evident, but only in late stages of the disease. Biphasic changes in spontaneous EPSCs are
evident in MSSNs from HD mice in which increased activity occurs early, but is followed by reduced activity in overtly symptomatic
mice. A similar pattern occurs with IPSC activity in cortical pyramidal neurons from HD mice. NMDA receptor activity (as measured by
current amplitude and density) and Mg
2+ sensitivity differ between cell types. RMP, resting membrane potential; VG, voltage-gated;
VGCC, voltage-gated calcium channels.
Properties Cortical pyramidal neurons MSSNs
Cell membrane properties
Membrane capacitance Reduced cell capacitance (L) (Cummings
et al., 2006, 2009)
Reduced cell capacitance (E, L) (Klapstein
et al., 2001; Cepeda et al., 2003)
Input resistance Increased membrane input resistance (L)
(Cummings et al., 2006, 2009)
Increased membrane input resistance (E, L)
(Klapstein et al., 2001; Cepeda et al., 2003)
RMP Depolarized resting membrane potentials
(L) (Cummings et al., 2006, 2009)
Depolarized resting membrane potentials (L)
(Klapstein et al., 2001)
VG channel activity
VGCCs Increased VGCC currents (L) (Andre ´ et al., 2006) Decreased VGCC currents (E) (Cepeda
et al., 2001)
K
+ channels Decreased K
+ channel inward rectification (E,
L) (Ariano et al., 2001; Klapstein et al., 2001)
Synaptic activity
EPSCs Increased spontaneous EPSC frequency (L)
(Cummings et al., 2009)
Decreased spontaneous EPSC frequency (L)
(Cepeda et al., 2003)
Increased evoked EPSCs (L)(Cummings
et al., 2009)
Large-amplitude spontaneous EPSCs (E)
(Cepeda et al., 2003)
Increased evoked EPSCs (E) (Joshi et al., 2009)
Decreased evoked EPSCs (L) (Joshi et al., 2009)
IPSCs Increased spontaneous IPSC frequency (E)
(Cummings et al., 2009)
Increased spontaneous IPSC frequency (L)
(Cepeda et al., 2004)
Decreased spontaneous IPSC frequency (L)
(Cummings et al., 2009)
Action potentials
Frequency Increased firing rate (E) (Walker et al., 2008) Increased firing rate (E) (Rebec et al., 2006;
Miller et al., 2008)
Correlated Activity Decreased synchrony between neuronal pairs
(E) ( Walker et al., 2008)
Decreased correlated firing (E) (Rebec et al.,
2006; Miller et al., 2008)
Receptors
NMDA receptors Decreased NMDA receptor currents (E)
(Andre ´ et al., 2006)
Increased NMDAR currents (E, L) (Cepeda
et al., 2001; Starling et al., 2005; Zeron
et al., 2002; Graham et al., 2009)
Increased NMDAR Mg
2+ sensitivity (E)
(Andre ´ et al., 2006)
Decreased NMDAR Mg
2+ sensitivity (E, L)
(Cepeda et al., 2001; Starling et al., 2005)
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1072005). One of the consequences of increases in membrane
input resistance is an enhancement of cell excitability which,
coupled with depolarized membrane potentials, could lead to
amplification of synaptic inputs and increased action
potential firing in MSSNs. Consistent with this idea, in vivo
recordings of striatal neurons demonstrated that cell firing is
elevated in R/2 transgenic relative to WT mice at 6–9 weeks
of age (Rebec et al., 2006). Not only the frequency, but also
the burst activity and correlated firing patterns were altered
in HD mice (Miller et al., 2008). Thus correlated firing and
coincident bursts between pairs of MSSNs were prominent in
cells from WT animals, but reduced in R6/2 and knock-in
models, suggesting that information processing at both the
single-neuron and population level is compromised in the
striatum of symptomatic HD mice (Miller et al., 2008). Similar
changes were also observed in cortical pyramidal neurons
(Walker et al., 2008).
GLUTAMATE AND GABA SYNAPTIC ACTIVITY IN
STRIATUM AND CORTEX
In neurons the htt protein distribution is very similar to that of
synaptophysin (Wood et al., 1996) and it has been shown to
associate with various proteins involved in synaptic function.
Mutant htt produces specific impairment of exocytosis and
endocytosis, potentially causing abnormal synaptic transmis-
sion, thus leading to the proposal that HD is a synaptopathol-
ogy (Li et al., 2003). Using genetic mouse models we were able
to examine the progression of synaptic alterations along the
corticostriatal pathway in HD. Since cortical neurons are
affected, we also examined synaptic changes in pyramidal
neurons. Our results showed that changes in synaptic
transmission are time- and region-dependent.
In R6/2 and YAC128 HD mice, alterations in glutamatergic
function along the corticostriatal pathway change dynamically
in a biphasic manner (Table 1). Although a progressive
reduction in spontaneous and evoked glutamatergic synaptic
activity, coinciding with the appearance of overt behavioural
alterations, is the most noticeable change in R6/2 mice
(Klapstein et al., 2001; Cepeda et al., 2003), dysregulation of
glutamatergic input occurs early and is manifested by the
presence of large-amplitude and complex synaptic events that
peak at approx. 5–7 weeks of age (Cepeda et al., 2003). These
large events could reflect increased cortical excitability and a
possible reduction in presynaptic receptor function, including
DA D2, metabotropic glutamate (mGluR2/3) and endocannabi-
noid CB1 receptors (Cha et al., 1998; Luthi-Carter et al., 2000;
Ariano et al., 2002). As striatal neuronal action potential
generation is highly dependent on cortical inputs, the presence
of large-amplitude synaptic events in the striatum of R6/2
mice at 5–7 weeks, in conjunction with higher membrane
input resistance, predicts transiently increased activity along
the corticostriatal pathway in a subset of MSSNs.
Hyperexcitability in cortical networks was confirmed in the
R6/2 and other mouse models. Examination of somatosensory
cortical pyramidal neurons in layers II/III in slices from R6/2
mice revealed that spontaneous EPSCs (excitatory postsynaptic
currents) occurred at a higher frequency in behaviourally
phenotypic mice, whereas spontaneous IPSCs (inhibitory
postsynaptic currents) were initially increased in frequency
and subsequently decreased at 80–90 days (Cummings et al.,
2009). Decreased inhibition in cortical pyramidal neurons,
manifested by a reduction in spontaneous IPSCs, was also
observed in the BACHD model at 6 months, when motor
dysfunction occurs (Spampanato et al., 2008). Furthermore,
compared with control animals, R6/2 mice demonstrate
increased epileptiform activity in cortical slices and seizure
susceptibility in vivo after blockade of GABAA receptors with
bicucullineandpicrotoxinrespectively(Cummingsetal.,2009).
Interestingly, in contrast with reduced IPSC frequency in the
cortex of symptomatic animals, the frequency of inhibitory
GABAA receptor-mediated synaptic events is increased in the
striatum of R6/2 and other models of HD (Cepeda et al., 2004;
Cummings et al., 2007). This observation predicts reduced
output of MSSNs to target structures along the direct and
indirect pathways. Increased GABA release also could dampen
glutamateinputseitherbyshunting (increase inthemembrane
conductance) or by activation of GABAB receptors located on
corticostriatal terminals.
Recently we examined alterations in glutamate release in
the corticostriatal pathway of YAC128 mice at different stages
of disease progression (1, 7 and 12 months), using combined
optical and electrophysiological methods. Similar to results
from R6/2 mice, the results in YAC128 mice demonstrated
biphasic age-dependent changes in corticostriatal function. At
1 month, before the behavioural phenotype develops,
glutamate release and AMPA (a-amino-3-hydroxyl-5-
methyl-4-isoxazole-propionate) receptor-mediated synaptic
currents evoked by cortical stimulation were increased. At 7
and 12 months, after the development of the behavioural
phenotype, glutamate release and AMPA synaptic currents
were significantly reduced (Joshi et al., 2009). These effects
were due to combined pre- and post-synaptic alterations.
The susceptibility to excitotoxic stress in YAC128 mice also
changes in a biphasic manner (Graham et al., 2009). At 1
month, before phenotypic changes occur, mice display
increased sensitivity to NMDA and quinolinic acid. In contrast,
at 7–10 months symptomatic mice are resistant to quinolinic
acid neurotoxicity. These changes are paralleled by increased
NMDA receptor-mediated synaptic currents in slices and
increased postsynaptic currents in acutely isolated MSSNs
from presymptomatic, followed by reduced currents in
symptomatic, YAC128 mice (Graham et al., 2009).
Multiple alterations in corticostriatal synaptic function also
depend on the pathogenicity of mutant htt (Milnerwood and
Raymond, 2007). Presynaptic dysfunction and a propensity
towards synaptic depression in YAC72 and YAC128 compared
with YAC18 mice occurs at 1 month. In YAC128 mice, reduced
AMPA responses evoked by intrastriatal stimulation were also
C Cepeda and others
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currents, postsynaptic NMDA currents were enhanced in all
three pathologic HD YAC variants (Milnerwood and Raymond,
2007).
One of the outcomes of excitatory activity in the
corticostriatal pathway is the concomitant release of BDNF
(brain-derived neurotrophic factor), a trophic factor essential
for postsynaptic neuronal support that is reduced in HD
(Zuccato and Cattaneo, 2007). Thus the progressive reduction
in glutamate synaptic activity will also reduce the release of
this important factor and potentially facilitate cellular
dysfunction and subsequent degeneration.
DIFFERENTIAL VULNERABILITY OF MSSNs
One of the enigmas of HD is the particular vulnerability of
MSSNs forming the indirect pathway. Decreased enk express-
ion is one of the earliest molecular markers of neuropathology
in HD mice (Menalled et al., 2000). What makes these neurons
more susceptible to degeneration? The EGFP (enhanced green
fluorescent protein) gene has been used as a reporter to
identify DA D1 (direct pathway) and D2 (indirect pathway)
receptor-expressing striatal cells. Several studies in MSSNs
from intact mice have shown that dendritic elaboration and
cell capacitance are reduced in D2 cells (Gertler et al., 2008).
We have examined and compared electrophysiology in D1 and
D2 receptor-expressing MSSNs. D2 receptor-expressing MSSNs
are more excitable and appear to be better connected to the
cerebral cortex than D1 cells. For example, cortical disinhibi-
tion using GABAA receptor blockers leads to the occurrence of
membrane depolarizations and bursts in D2 receptor-expres-
sing, but not in D1 receptor-expressing, MSSNs (Cepeda et al.,
2008), confirming previous studies showing selective activa-
tion of enk-containing neurons using expression of imme-
diate-early gene proteins, Fos and Jun B, after cortical
disinhibition (Berretta et al., 1997; Parthasarathy and
Graybiel, 1997). The size of corticostriatal glutamatergic
boutons synapsing on to D2 receptor-expressing MSSNs is
largerthan those contacting D1receptor-expressingMSSNs, as
shown by electron microscopy (Reiner et al., 2003). This finding
implies that D2 receptor-expressing MSSNs are subjected to
increased glutamate release at the synapse. Perhaps these
differences in glutamate release make striatal D2 cells more
susceptible to degeneration in HD.
MECHANISMS OF NEURONAL DEGENERATION
IN HD
How do the electrophysiological findings reviewed here
contribute to our understanding of neuronal dysfunction
and degeneration in HD? The findings from studies of mouse
models permit the generation of a model of neuronal
dysfunction and degeneration that may be applicable to
the human disease (Figure 1). The starting point is dysregula-
tion of glutamate release along the corticostriatal pathway
and altered modulation by presynaptic receptors, followed by
a series of physiological, compensatory mechanisms that
attempt to counter the change in glutamate release.
Compensatory mechanisms are effective initially but, even-
tually, they can have deleterious effects. It is worth
mentioning that a similar mechanism, i.e. calcium-dependent
increase in neurotransmitter release as the root of neuronal
degeneration, was also postulated in a Drosophila model of
HD (Romero et al., 2008).
The function of normal htt is not well understood, but
convergent evidence points to this protein having a role in
vesicular trafficking, exocytosis and endocytosis (DiFiglia et
al., 1995; Caviston and Holzbaur, 2009). Elongation of the
CAG tract leads to alterations in the synaptic machinery
producing initial increases in glutamate release reflected by
enhanced synaptic responses and large amplitude spontan-
eous synaptic events. Excess glutamate release causes the
collapse of spines on postsynaptic MSSNs, which in turn
increases membrane input resistance, reduces K
+ conduc-
tances, and further amplifies synaptic signals. Dysregulation
of glutamate release is compounded by loss of DA D2, CB1,
mGluR2/3 and other presynaptic receptors regulating glutam-
ate release at corticostriatal terminals. A compensatory
mechanism might be the increase of GABAergic synaptic
activity that occurs within the striatum. Increasing
GABAergic synaptic transmission could aid in preventing
further neuronal damage by reducing glutamate release, by
activation of presynaptic GABAB receptors, and/or inducing
postsynaptic alterations by shunting excitatory inputs to
MSSNs, via GABAA receptors.
The period of increased glutamate release in the striatum
will be followed by a period of reduced synaptic input.
Another adverse effect of reduced corticostriatal commun-
ication is the reduced release of BDNF. Lack of this trophic
factor will negatively impact MSSNs. During this time, K
+
conductances are also reduced, and the resting membrane
potential is depolarized, leading to an increased propensity
for MSSNs to produce action potentials. Although these cells
will fire more frequently, their firing patterns are now
disorganized.
Why should changes occur earlier and/or be more evident
in MSSNs of the indirect pathway? One possible reason is that
these cells appear to be more connected to cortical pyramidal
neurons, and reduced corticostriatal communication will first
affect this subpopulation of cells. Enk expression is tightly
regulated by cortical inputs (Uhl et al., 1988) and decreased
cortical communication will reduce enk expression in these
MSSNs.
Reductions in spine density and synaptic markers cause a
redistribution of postsynaptic glutamate receptors that is also
deleterious in neurons. Synaptic NMDA receptors activate a
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109pro-survival cascade and BDNF transcription. In contrast,
extrasynaptic NMDA receptors (rich in NR2B subunits)
activate a pro-apoptotic cascade (Papadia and Hardingham,
2007). In the striatum of HD mice, there is evidence of
increased extrasynaptic NMDA receptor expression and
signalling (Milnerwood et al., 2010). Thus the balance
between synaptic and extrasynaptic activity determines
neuronal survival (Okamoto et al., 2009; Levine et al.,
2010). Interestingly, synaptic activity is required for inclusion
formation which, in turn, is believed to be neuroprotective
(Okamoto et al., 2009).
FUTURE DIRECTIONS
Many unanswered questions still remain. A major one
concerns the role of brain regions other than the striatum
and cortex in HD manifestations. In humans with HD there is
evidence of significant cell loss within the thalamus (Heinsen
et al., 1996) and hypothalamus (Kremer et al., 1990). The
thalamus, particularly the centromedian and parafascicular
nuclei, is the origin of a second major glutamatergic input to
the striatum (Smith et al., 2004). The nature of these inputs is
just beginning to be unravelled in slice preparations that
preserve both cortico- and thalamo-striatal inputs (Ding et
al., 2008; Smeal et al., 2008). It will be important to
determine whether this pathway also plays a role in the
alterations of excitatory synaptic activity that are observed in
HD mouse models.
Another area that has not been extensively investigated is
the function of glial cells and glio-neuronal interactions in
HD. How are astrocytes and glutamate transporters changed
in HD and how do they modulate neuronal degeneration?
Initial evidence points to an important role of mutant htt in
astrocytes, which might lead to decreased levels of glutamate
transporters (Lievens et al., 2001; Shin et al., 2005; Estrada-
Sanchez et al., 2009). The contribution of glial cells to disease
progression further supports a non-cell autonomous process
in HD (Lobsiger and Cleveland, 2007).
CONCLUSIONS
Genetic mouse models of HD have become important tools
for examining the natural evolution of the disease and
understanding its mechanisms. Convergent evidence supports
cell-autonomous and non-cell autonomous processes in
neuronal dysfunction and subsequent degeneration. In
particular, striatal neuronal dysfunction seems to depend
on both intrinsic changes in NMDA receptor sensitivity, as
Figure 1 Simplified model of early and late changes in excitatory and inhibitory synaptic transmission within the cerebral cortex and
striatum of HD mouse models
MSSNs in the striatum receive excitatory inputs from the cortex and inhibitory inputs mainly from local interneurons. Early in the
disease and coinciding with overt symptoms, dysregulation of corticostriatal input produces increased excitation and firing of
MSSNs, increasing striatal output to the external segment of the globus pallidus (GPe) and to the substantia nigra pars reticulata
(SNr). Late in the disease, in spite of increased cortical excitability, excitatory corticostriatal input is decreased while inhibitory
activity is increased, leading to the obliteration of striatal output. In the Figure, neuronal projections coloured in red are excitatory,
whereas those in blue are inhibitory.
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before overt symptoms emerge, and are biphasic in nature,
with age-dependent increases followed by decreases in
excitatory transmission along the corticostriatal pathway. In
terms of therapeutics, structural and functional changes are
time- and region-dependent. In consequence, treatments
should be tailoured to different stages of the disease and be
specific to different brain areas.
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